October 12, 2022 – Pritzker Levine is pleased to announce that the firm will be honored by the American Antitrust Institute’s Antitrust Enforcement Awards for their work in In re EpiPen Marketing, Sales Practices and Antitrust Litigation. Pritzker Levine will be …
September 1, 2022 – Pritzker Levine is pleased to announce that partner Elizabeth C. Pritzker has been named the 2022 “Antitrust Lawyer of the Year” by the Antitrust and Unfair Competition Law Section of the California Lawyers Association. Elizabeth will …
Elizabeth C. Pritzker Named the 2022 “Antitrust Lawyer of the Year” Read More »
July 11, 2022 – Judge Daniel D. Crabtree has granted final approval to the $264 million settlement between Plaintiffs and the Mylan Defendants in In re: EpiPen Marketing, Sales Practices and Antitrust Litigation, MDL No. 2785, finding the settlement to …
March 1, 2022 – Plaintiffs in In re: EpiPen Marketing, Sales Practices and Antitrust Litigation, MDL No. 2785, have reached a $264 million settlement with the Mylan Defendants to resolve class claims that Mylan, together with the Pfizer Defendants, engaged …
Plaintiffs Reach Settlement with the Mylan Defendants in EpiPen Class Action Read More »
November 17, 2021 – Today, Judge Daniel D. Crabtree granted final approval of the settlement between Plaintiffs and the Pfizer Defendants in In re: EpiPen Marketing, Sales Practices and Antitrust Litigation, MDL No. 2785, proceeding in the United States District …